Dyfyniad APA

Lubaba, A., & Fariha, L. M. (2024). PCSK9i: Proprotein convertase subtilisin/kexin type 9 inhibitor a new phase of lipid-lowering treatment. Brac University.

Dyfyniad Arddull Chicago

Lubaba, Anikah, and Luluel Maknun Fariha. PCSK9i: Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor a New Phase of Lipid-lowering Treatment. Brac University, 2024.

Dyfyniad MLA

Lubaba, Anikah, and Luluel Maknun Fariha. PCSK9i: Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor a New Phase of Lipid-lowering Treatment. Brac University, 2024.

Rhybudd: Mae'n bosib nad yw'r dyfyniadau hyn bob amser yn 100% cywir.